GILEAD SCIENCES INC

Gilead Sciences executive share trades: Form 4 & Form 144 filings show routine purchases and sales, confirming regulatory compliance while the biotech pipeline advances toward future approvals.

Gilead Sciences’ latest quarterly report shows $3.1 B in revenue and $1.3 B profit, highlighting its antiviral and oncology pipeline, the potential Remdesivir‑Ebola EUA, and partnership moves that could boost future shareholder value.

Gilead’s Q2 2026 earnings show $7.8B revenue growth driven by HIV and NASH drugs, yet acquisition‑driven R&D charges turn the period into a net loss.

Gilead Sciences Q4 earnings on Aug 4, 2026: see how safety, efficacy data and regulatory updates could shift biopharma valuations and market momentum.

Gilead’s new Ebola trial in the DRC shows how remdesivir could capture a $12 bn outbreak‑phase market, boosting revenue, ROI and brand trust while offering cost‑effective, rapid‑response therapy.

Gilead’s platform‑driven strategy expands beyond oncology, delivering promising cell‑based therapies for autoimmune, cardiovascular, and infectious diseases with solid safety and regulatory progress.

Explore how Gilead Sciences’ focus on antivirals drives stock performance, clinical success, and regulatory wins—insights that shape investor outlook.

Gilead Sciences’ steady Q4 results show modest revenue growth, a robust hepatitis‑B launch, and a diversified Phase III pipeline that may drive future gains.

Gilead’s FDA acceptance of Yeztugo’s sNDA marks a key milestone for its once‑weekly HIV PrEP, while insider share sales confirm routine liquidity activity and highlight investor confidence.

Gilead Sciences Q1 2026 earnings hit $1.34 EPS, yet analyst targets swing from $90 to $135 as new hepatitis‑B and immuno‑oncology candidates promise upside, while patent expirations loom.